A detailed history of Legal & General Group PLC transactions in Landec Corp \Ca\ stock. As of the latest transaction made, Legal & General Group PLC holds 1,851 shares of LNDC stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,851
Holding current value
$0
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
N/A
1,851 New
1,851 $0
Q3 2022

Nov 14, 2022

BUY
$8.57 - $11.57 $3,479 - $4,697
406 Added 18.13%
2,645 $24,000
Q2 2022

Aug 22, 2022

BUY
$8.84 - $11.64 $1,573 - $2,071
178 Added 8.64%
2,239 $22,000
Q4 2021

Feb 14, 2022

SELL
$7.95 - $11.24 $74,245 - $104,970
-9,339 Reduced 81.92%
2,061 $23,000
Q3 2021

Nov 15, 2021

BUY
$9.22 - $12.44 $53,429 - $72,089
5,795 Added 103.39%
11,400 $105,000
Q2 2021

Aug 12, 2021

SELL
$9.91 - $12.78 $2,259 - $2,913
-228 Reduced 3.91%
5,605 $63,000
Q3 2020

Nov 13, 2020

SELL
$7.59 - $10.8 $8,531 - $12,139
-1,124 Reduced 16.16%
5,833 $56,000
Q1 2020

May 14, 2020

SELL
$7.69 - $11.68 $6,528 - $9,916
-849 Reduced 10.88%
6,957 $61,000
Q4 2019

Feb 13, 2020

BUY
$9.09 - $11.89 $5,126 - $6,705
564 Added 7.79%
7,806 $88,000
Q3 2019

Nov 13, 2019

BUY
$9.66 - $12.36 $25,173 - $32,210
2,606 Added 56.21%
7,242 $79,000
Q1 2019

May 15, 2019

SELL
$10.35 - $13.06 $6,696 - $8,449
-647 Reduced 12.25%
4,636 $57,000
Q4 2018

Feb 15, 2019

BUY
$11.64 - $15.41 $16,307 - $21,589
1,401 Added 36.09%
5,283 $62,000
Q2 2018

Aug 10, 2018

SELL
$13.05 - $15.45 $8,860 - $10,490
-679 Reduced 14.89%
3,882 $58,000
Q1 2018

May 17, 2018

SELL
$12.0 - $14.45 $32,712 - $39,390
-2,726 Reduced 37.41%
4,561 $60,000
Q4 2017

Feb 13, 2018

BUY
$11.65 - $13.35 $84,893 - $97,281
7,287
7,287 $90,000

Others Institutions Holding LNDC

About LANDEC CORP \CA\


  • Ticker LNDC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 29,595,600
  • Description
  • Landec Corporation operates as a diversified health and wellness company. The company manufactures pharmaceutical-grade sodium hyaluronate (HA)-based biomaterials for primary use in the ophthalmic and orthopedic markets. It also provides product development services to its partners for HA-based, as well as non-HA based, aseptically formulated, a...
More about LNDC
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.